DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO

摘要

The invention encompasses methods for treating or preventing diseases and disorders associated abnormal cell growth, for example, treating or preventing cancer or tumor growth, by administering to a subject in need thereof a composition comprising a therapeutically or prophylactically effective amount of a compound that downregulates DDX3, for example a fused diimidazodiazepine ring compound or a pharmaceutically acceptable salt thereof. The invention also encompasses the use of DDX3 as a biomarker for diagnostic and treatment purposes, for example, to identify a hyperproliferative disorder susceptible to treatment by down regulation of DDX3.

主权项

1. A method of identifying a subject having a hyperproliferative disorder susceptible to treatment by down regulation of DDX3 comprising:
a) obtaining a cell or tissue sample from tissue of the subject associated with or suspected to be associated with the disorder; b) optionally isolating cells from the tissue; c) measuring expression of DDX3 in the tissue or in the cells isolated from the tissue using qRT-PCR and the PCR primers and probes specific for DDX3, or using immunohistochemistry and antibodies specific for DDX3 or an antigen binding fragment thereof; d) providing a reference non-neoplastic tissue sample; e) comparing the level of expression of the DDX3 gene from the tissue sample of the subject, to the level of expression of the DDX3 gene of in a reference non-neoplastic tissue sample; and f) identifying the subject as having the hyperproliferative disorder as susceptible to treatment by down regulation of DDX3 if DDX3 is expressed at an increased level in the tissue or cell sample of the subject when compared to the reference non-neoplastic tissue sample.